- Tipos de Cáncer
Tipos de Cáncer
Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.A a la Z - Tratamiento
Tratamiento del Cáncer
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
- Riesgo de concer y prevencion
- Drogas de Cáncer
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
- Lidiando
Lidiando con el Cáncer
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
- Profesionales de la salud
- Estudios Clínicos
Notas para enfermeros 
¿Cuál es mi riesgo? k? 
OncoPilot: Manejando su experiencia del cáncer 
OncoLink Cancer Blogs
Community Events Calendar 
Abramson Cancer Center 
NCI CANCERLIT® Search: Hodgkin's Disease - May 2002
National Cancer Institute®
Ultima Vez Modificado: 1 de mayo del 2002
Table of Contents
1
UI - 1383821
AU - Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES;
TI -
Green MR; Gottlieb A; Peterson BA
Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP
alternating with ABVD.
SO - N Engl J Med 1992 Nov 19;327(21):1478-84
AD - Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
02115.
BACKGROUND AND METHODS. MOPP (mechlorethamine, vincristine,
procarbazine, and prednisone) has been the standard treatment for
Hodgkin's disease for almost 20 years. In a randomized, multicenter
trial, we compared three regimens of primary systemic therapy for newly
diagnosed advanced Hodgkin's disease in Stages IIIA2, IIIB, and IVA or
IVB: (1) MOPP alone given for 6 to 8 cycles, (2) MOPP alternating with
ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) for 12
cycles, and (3) ABVD alone for 6 to 8 cycles. Patients in a first
relapse after radiation therapy were eligible. No additional radiation
therapy was given. Patients who did not have a complete response or who
had a relapse with either MOPP alone or ABVD alone were switched to the
opposite regimen. RESULTS. Of 361 eligible patients, 123 received MOPP,
123 received MOPP alternating with ABVD, and 115 received ABVD alone.
The patients were stratified according to age, stage, previous
radiation, histologic features, and performance status. The overall
response rate was 93 percent, with complete responses in 77 percent: 67
percent in the MOPP group, 82 percent in the ABVD group, and 83 percent
in the MOPP-ABVD group (P = 0.006 for the comparison of MOPP with the
other two regimens, both of which contained doxorubicin). The rates of
failure-free survival at five years were 50 percent for MOPP, 61 percent
for ABVD, and 65 percent for MOPP-ABVD. Age, stage (III vs. IV), and
regimen influenced failure-free survival significantly. Overall survival
at five years was 66 percent for MOPP, 73 percent for ABVD, and 75
percent for MOPP-ABVD (P = 0.28 for the comparison of MOPP with the
doxorubicin regimens). MOPP had more severe toxic effects on bone marrow
than ABVD and was associated with greater reductions in the prescribed
dose. CONCLUSIONS. In this trial, ABVD therapy for 6 to 8 months was as
effective as 12 months of MOPP alternating with ABVD, and both were
superior to MOPP alone in the treatment of advanced Hodgkin's disease.
ABVD was less myelotoxic than MOPP or ABVD alternating with MOPP.
2
UI - 11986425
AU - Canellos GP; Niedzwiecki D
TI -
Long-term follow-up of Hodgkin's disease trial.
SO - N Engl J Med 2002 May 2;346(18):1417-8
3
UI - 11858975
AU - Raemaekers J; Kluin-Nelemans H; Teodorovic I; Meerwaldt C; Noordijk E;
TI -
Thomas J; Glabbeke M; Henry-Amar M; Carde P
The achievements of the EORTC Lymphoma Group. European Organisation for
Research and Treatment of Cancer.
SO - Eur J Cancer 2002 Mar;38 Suppl 4():S107-13
AD - Deptartment of Hematology, University Medical Centre Nijmegen, PO Box
9101, 6500 HB, Nijmegen, The Netherlands. j.raemaekers@hemat.azn.nl
From 1964 onwards, the EORTC Lymphoma Group has conducted seven
consecutive randomised phase 3 trials on early stage Hodgkin's lymphoma
aiming at increasing efficacy, while decreasing short- and long-term
toxicity. Staging laparotomy is definitely abandoned and replaced by
identification of prognostic subgroups based on pretreatment clinical
characteristics. Event-free and overall survival significantly improved
from about 50 and then 70%, in the early years, to over 80 and then 90%
more recently. Radiotherapy fields have become more restricted, whereas
chemotherapy has become standard. Longitudinal quality-of-life
assessment has become an integral part of our studies. In advanced
stages, overall outcome has improved as well with 6-year survival rates
of over 80%. In aggressive types of NHL, the second generation
chemotherapy schedule CHVmP-BV was superior to CHVmP. We could not show
any advantage for intensification of upfront treatment with autologous
stem cell transplantation.
4
UI - 11971184
AU - Horie R; Watanabe T; Morishita Y; Ito K; Ishida T; Kanegae Y; Saito I;
TI -
Higashihara M; Mori S; Kadin ME; Watanabe T
Ligand-independent signaling by overexpressed CD30 drives NF-kappaB
activation in Hodgkin-Reed-Sternberg cells.
SO - Oncogene 2002 Apr 11;21(16):2493-503
AD - Division of Pathology, The Institute of Medical Science, The University
of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
Overexpression of CD30 and constitutive NF-kappaB activation
characterizes tumor cells of Hodgkin's disease (HD), Hodgkin and
Reed-Sternberg (H-RS) cells. We report that in H-RS cells overexpression
of CD30 leads to self-aggregation, recruitment of TRAF2 and TRAF5, and
NF-kappaB activation, independent of CD30 ligand. CD30 and TRAF proteins
co-localized in H-RS cell lines and in lymph nodes of HD. An
adenovirus-vector carrying a decoy CD30 lacking the cytoplasmic region
or a dominant negative IkappaBalpha mutant blocks NF-kappaB activation,
down regulates IL-13 expression and induces apoptosis. Thus, in H-RS
cells, ligand-independent activation of CD30 signaling drives NF-kappaB
activation and this leads to constitutive cytokine expression, which
provides a molecular basis for HD. Inhibition of NF-kappaB activation by
adenovirus vector-mediated gene transfer may provide a novel strategy of
cell- and target molecule-specific therapy for patients with HD.
5
UI - 11216711
AU - Hamilton VM; Norris C; Bunin N; Goldwein JW; Bunin GR; Lange B; Meadows
TI -
AT
Cyclophosphamide-based, seven-drug hybrid and low-dose involved field
radiation for the treatment of childhood and adolescent Hodgkin disease.
SO - J Pediatr Hematol Oncol 2001 Feb;23(2):84-8
AD - Division of Oncology, Children's Hospital of Philadelphia, Pennsylvania
19104, USA.
PURPOSE: The outlook for children and adolescents with Hodgkin disease
(HD) is excellent with combined modality therapy. However, the long-term
toxicities of multiagent therapy and radiation therapy remain of concern
for these patients with curable disease. In an attempt to reduce
long-term toxicities while preserving excellent cure rates, we developed
a combined-modality protocol using a modified seven-drug hybrid and
low-dose (2,000 cGy) involved field radiation therapy (RT). The hybrid
used cumulative doses of alkylating agents and anthracyclines that were
lower than those used in previous four-drug regimens and substituted a
less leukemogenic agent, cyclophosphamide, for nitrogen mustard.
PATIENTS AND METHODS: From 1991 through 1994 a cyclophosphamide,
vincristine, procarbazine, and prednisone/adriamycin, bleomycin, and
vinblastine hybrid was used to treat 29 patients with HD. Median age was
12 years (range 6-16 yrs). Patients who were postpubertal with early
stage disease as determined by surgical staging were excluded. Treatment
consisted of four cycles of therapy for stages I and IIA, six cycles for
stages IIB and III, and eight cycles for stage IV. Twenty-two patients
also received low-dose RT to areas of bulky disease. RESULTS:
Twenty-eight patients (97%) had a complete response to chemotherapy.
Five patients experienced relapse; two died from disease 27 and 29
months after initial diagnosis; three received additional therapy and
are alive with no evidence of disease. Follow-up for all other patients
is a median of 56 months (range 24-78 mos) from cessation of therapy and
all have remained disease-free. At 5 years follow-up, actuarial
disease-free survival is 82%, and the overall survival is 93%. There
have been no clinically significant cardiac or pulmonary toxicities and
no secondary malignancies. CONCLUSIONS: This therapy has resulted in
5-year overall survival and disease-free survival rates similar to
regimens using higher doses of alkylating agents, anthracyclines, and
radiation. Longer follow-up will be necessary to fully evaluate
disease-free survival, organ damage, and quality of life.
6
UI - 11563772
AU - Nitschke R
TI -
Cyclophosphamide-based, seven-drug hybrid and low-dose involved field
radiation for the treatment of childhood and adolescent Hodgkin disease.
SO - J Pediatr Hematol Oncol 2001 Aug-Sep;23(6):368-9
7
UI - 11808913
AU - Sasahara Y; Fujie H; Kumaki S; Ohashi Y; Minegishi M; Tsuchiya S
TI -
Epstein-Barr virus-associated hodgkin's disease in a patient with
Wiskott-Aldrich syndrome.
SO - Acta Paediatr 2001 Nov;90(11):1348-51
AD - Department of Pediatric Oncology, Institute of Development, Aging and
Cancer, Tohoku University, Miyagi, Japan.
Wiskott-Aldrich syndrome is a primary immunodeficiency syndrome in which
the majority of malignant complications are non-Hodgkin's lymphoma. We
report here a Wiskott-Aldrich syndrome patient who developed
Epstein-Barr virus-positive Hodgkin's disease in the bilateral pulmonary
hilar lymph nodes. The treatment was successful as the patient achieved
a complete response and event-free survival for more than 4 y.
CONCLUSION: This case is very rare, but highly suggestive of the
immune-mediated mechanisms in the pathogenesis of Epstein-Barr
virus-associated Hodgkin's disease in an immunodeficiency patient.
8
UI - 11792415
AU - Glaser SL; Hsu JL
TI -
Hodgkin's disease in Asians: incidence patterns and risk factors in
population-based data.
SO - Leuk Res 2002 Mar;26(3):261-9
AD - Northern California Cancer Center, 32960 Alvarado-Niles Road, Suite 600,
Union City, CA 94587, USA. sglaser@nccc.org
Hodgkin's disease (HD) has been reported to be rare in Asians. Data
sparseness has hindered studies exploring the relative contributions of
environment and heredity to HD etiology, and individual risk factors
have never been studied in an Asian population. With the most recent,
uniformly collected population-based data from the US and Asia, we
compared HD incidence rates in Chinese, Japanese, Filipinos, and Asian
Indians in the US and in Asia. HD incidence rates were quite low in all
Asian subgroups, but approximately double in US Asians as in native
Asians. In both, rates were lower for Japanese and Chinese than for
Filipinos and Asian Indians. A modest young-adult rate peak occurred for
most US Asian groups, but not for any population in Asia. In data from a
population-based case-control study of HD in San Francisco area women,
young-adult Asian cases, like young-adult cases of other racial/ethnic
groups, had childhood social environments indicative of less early
contact with children. Given environmental and lifestyle differences
between the US and Asia, the consistently low rates of HD in Asians
suggest genetic resistance to disease development, possibly associated
with HLA type. International and inter-ethnic differences, and risk
factor patterns in case-control data, implicate environmental influences
in the etiology of HD.
9
UI - 11921013
AU - Fung HC; Nademanee AP
TI -
Approach to Hodgkin's lymphoma in the new millennium.
SO - Hematol Oncol 2002 Mar;20(1):1-15
AD - Division of Hematology/Bone Marrow Transplantation, City of Hope
National Medical Center, Duarte, CA 91010, USA. hfung@coh.org
Approximately 75% of patients with Hodgkin's lymphoma can be cured with
modern chemotherapy and radiation. Most patients are treated according
to clinical stage and the associated prognostic factors. For patients
with limited stage Hodgkin's lymphoma, combined modality treatment has
replaced subtotal nodal irradiation as the preferred treatment option.
This approach eliminates laparotomy and potentially decreases the
long-term toxicity secondary to extended field irradiation and
splenectomy. Furthermore, recent studies suggest that it may improve
disease control and possibly survival. Multiple novel regimens have been
tested in the past 20 years in patients with advanced Hodgkin's lymphoma
including dose-intense regimens, but current evidence suggests that ABVD
remains the treatment of choice outside clinical trials. Over the past
decade, the treatment-related morbidity and mortality associated with
autologous stem cell transplantation have reduced significantly and stem
cell transplant is becoming the treatment of choice for most patients
with primary refractory or recurrent Hodgkin's lymphoma. With longer
follow-up, long-term complications, in particular secondary malignancy
have become the leading cause of late treatment failure for patients
with Hodgkin's lymphoma. To improve the overall outcome of patients with
Hodgkin's lymphoma, future studies need to focus on reducing the
therapy-related toxicity for patients with good risk disease as well as
improving disease control for patients with poor risk disease through a
risk-adapted approach. Copyright 2001 John Wiley & Sons, Ltd.
10
UI - 11859311
AU - Cataldi A; Sardo P; Ventilii G; Guerrasio A; Pilastrino C; Saglio G;
TI -
Fava C
Extranodal Hodgkin lymphoma with renal, splenic and uterine involvement.
A case report.
SO - Radiol Med (Torino) 2002 Jan-Feb;103(1-2):130-3
AD - Dipartimento di Scienze Cliniche e Biologiche, Servizio di Radiologia a
Direzione Universitaria, Ospedale S. Luigi di Orbassano, Orbassano,
Torino, Italy.
11
UI - 11920617
AU - Ohshima K; Tutiya T; Yamaguchi T; Suzuki K; Suzumiya J; Kawasaki C;
TI -
Haraoka S; Kikuchi M
Infiltration of Th1 and Th2 lymphocytes around Hodgkin and
Reed-Sternberg (H&RS) cells in Hodgkin disease: Relation with expression
of CXC and CC chemokines on H&RS cells.
SO - Int J Cancer 2002 Apr 1;98(4):567-72
AD - Department of Pathology, School of Medicine, Fukuoka University,
Fukuoka, Japan. ohshima@fukuoka-u.ac.jp
Hodgkin disease (HD) is characterized by the presence of Hodgkin and
Reed-Sternberg cells (H&RS) and a prominent lymphocytic infiltration.
Various CXC and CC chemokines [e.g., interferon-gamma-inducible
protein-10 (IP10), monokine induced by interferon-gamma (MIG) and TARC]
are expressed on H&RS cells. Our study was designed to investigate the
expression of MIG, IP10 and TARC on H&RS cells and their relations on
lymphocyte infiltration. Immunohistochemical staining was performed
using antibodies for CXCR3 (a specific receptor for IP10 and MIG), which
is characteristic of Th1 helper phenotype and CCR3, CCR4 and ST2, which
are features of Th2 cells. We studied 15 cases of HD [lymphocyte
predominance (LP) type, 2; mixed cellularity (MC) type, 6; and nodular
sclerosis (NS) type, 7]. All 6 MC cases contained TARC-, IP10- and
MIG-expressing H&RS cells, however only 2 of 5 NS cases contained
TARC-expressing H&RS cells, 3 of 7 NS contained MIG-expressing H&RS
cells and only 1 of 7 NS contained IP10-expressing H&RS cells. Neither
of the 2 LP cases contained HR&S cells that expressed these chemokines.
The chemokines were more frequently expressed by MC than by NS and LP
types. IP10-, MIG- and TARC-positive HD cases contained higher numbers
of Th2 lymphocytes (ST2- CCR3- or CCR4-positive lymphocytes), compared
to IP10-, MIG- and TARC-negative HD cases (p < 0.05 or <0.5). The number
of CXCR3 (MIG and IP10 receptor)-positive lymphocytes (Th1 lymphocytes)
was not different between MIG- and IP10-positive and -negative HD.
Lymphocytes surrounding MIG- and IP10-positive H&RS cells were more
frequently CXCR3-positive, however, compared to MIG- and IP10-negative
cases. The CCR4 (TARC receptor)-positive lymphocytes, surrounding H&RS
cells, were minority and the surrounding lymphocytes were not different
between TARC-positive and negative cases. Our results indicate that MIG,
IP10 and TARC chemokines influenced the response of Th2 cells in HD. It
is possible, however, that IP10 and MIG may locally influence Th1 cells
via cell migration. Copyright 2002 Wiley-Liss, Inc.
12
UI - 11762530
AU - Cunzhi H; Jiexian J; Xianwen Z; Jingang G; Suling H
TI -
Classification and prognostic value of serum copper/zinc ratio in
Hodgkin's disease.
SO - Biol Trace Elem Res 2001 Nov;83(2):133-8
AD - Department of Etiology, Shanxi Cancer Institute, Taiyuan, People's
Republic of China.
The serum copper and zinc levels were determined by atomic absorption
spectrometry in 135 Hodgkin's disease (HD) patients and in 100 healthy
controls. These values were used to explore the application value of the
serum copper/zinc ratio in the histologic classification and prognosis
in this illness. The resuls show that serum copper and the copper/zinc
ratio were higher and the serum zinc level was lower in the HD patients
when compared to the healthy individuals (p < 0.01, 0.001, and 0.01,
respectively). The serum copper and copper/zinc ratio were significantly
higher in the lymphocyte-depleted type of HD than in the patients with
the mixed-cellular type of HD. These values were also higher and the
serum zinc was lower in the patients with mixed-cellular HD when
compared to the nodular-sclerosis and the lymphocyte-predominant types
of the disease (p < 0.01 and 0.001, respectively). It was also shown
that as the disease progresses, the serum copper level and copper/zinc
ratio rises with the concomitant decrease of the corresponding serum
zinc level. These trends are reversed in cases where the disease is in
remission. Both the serum copper level and the copper/zinc ratio were
strongly correlated to histopathological changes, clinical stage, and
prognosis of Hodgkin's disease.
13
UI - 11699213
AU - Preciado MV; De Matteo E; Fallo A; Chabay P; Drelichman G; Grinstein S
TI -
EBV-associated Hodgkin's disease in an HIV-infected child presenting
with a hemophagocytic syndrome.
SO - Leuk Lymphoma 2001 Jun;42(1-2):231-4
AD - Laboratory of Virology, Ricardo Gutierrez Children Hospital, Gallo 1330,
1425 Ciudad de Buenos Aires, Argentina. preciado@conicet.gov.ar
An 8-years-old boy was admitted with fever of unknown origin, cervical
lymphadenopathy and hepatosplenomegaly and weight loss. His mother's HIV
infection was diagnosed two weeks before his hospitalization, so he was
diagnosed as perinatally acquired AIDS. Serology and serial cultures
were negative for viral infections, toxoplasmosis, chagas, tuberculosis
and atypical mycobacterium. The patient met clinical and laboratory
criteria for hemophagocytic syndrome (HS) that was confirmed on bone
marrow aspirate and biopsy. A cervical lymph node biopsy was performed
which was diagnosed as Hodgkin's disease (HD) diffuse fibrosis
lymphocyte depletion subtype. EBERs in situ hybridization and LMP-1
immunohistochemistry on the lymph node biopsy established the EBV
association. On the basis of a sequence of appearance of the clinical,
laboratory and histological signs, HIV, EBV or HD may have triggered HS
as the last fatal event in this pediatric patient.
14
UI - 11836600
AU - Shen YY; Kao A; Yen RF
TI -
Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and
gallium-67 citrate scintigraphy for detecting malignant lymphoma.
SO - Oncol Rep 2002 Mar-Apr;9(2):321-5
AD - Department of Nuclear Medicine and PET Center, Shin Kong Wu Ho-Su
Memorial Hospital, Taiwan.
This study evaluates and compares the accuracy of positron emission
tomography with 18F-fluoro-2-deoxyglucose (FDG-PET) and gallium-67
citrate (Ga-67) scintigraphy in identifying disease sites in patients
with malignant lymphoma at initial diagnosis or relapse. Histology
subgroups included low (n=5), intermediate (n=6), high-grade (n=5)
non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) (n=14).
Ann-Arbor staging included 7 patients in stage I, 8 in stage II, 9 in
stage II, 6 in stage IV and 11 extra-nodal. In this study, before any
therapy, 25 contemporaneous FDG-PET and Ga-67 scintigraphies were
performed on patients with either NHL (16) or HD (14). One hundred and
eleven sites of disease were correlated on a site-by-site basis in
corresponding areas of FDG-PET and Ga-67 scintigraphy. Discordant
FDG-PET and Ga-67 scintigraphic findings were correlated with CT/MRI and
clinical evaluation. FDG-PET detected malignant lymphoma in 24/25
patients (sensitivity: 96.0%). There was a false-negative FDG-PET result
in only 1 patient with low-grade gastric malignant lymphoma. Ga-67
scintigraphy detected malignant lymphoma in 18/25 patients (sensitivity:
72.0%). There were false-negative Ga-67 scintigraphic results in 4 cases
with low-grade non-Hodgkin's lymphoma, 2 cases with bone or bone marrow
involvement, and 3 smaller disease sites. FDG-PET upstaged 6 patients in
whom Ga-67 scintigraphy detected disease sites partially. In imaging
lymphoma prior to therapy, FDG-PET had a higher sensitivity and detected
significantly more disease sites when compared with Ga-67 scintigraphy
in the initial evaluation of this group of patients. Upstaging of
patients with FDG-PET may result in a change in treatment strategy.
However, evaluation of the final sensitivity, specificity and accuracy
of these imaging modalities will need a further study with a larger
patient number.
15
UI - 11836623
AU - Spector N; Costa MA; Morais JC; Biasoli I; Solza C; De Fatima Gaui M;
TI -
Ferreira CG; Portugal RD; Loureiro M; Nucci M; Pulcheri W
Intensified ABVP chemotherapy for the primary treatment of Hodgkin's
disease.
SO - Oncol Rep 2002 Mar-Apr;9(2):439-42
AD - Hematology Service, School of Medicine and University Hospital, Federal
University of Rio de Janeiro, Rio de Janeiro 22461-150, Brazil.
spector@ufrj.br
This report describes the results of a multicenter study designed to
determine the efficacy and toxicity of a novel combination (ABVP) in
patients with newly diagnosed Hodgkin's disease. The ABVP protocol is a
modification of ABVD in which prednisone is substituted for DTIC. In
order to attempt an increase in drug intensity, doxorubicin, bleomycin
and vinblastine were administered on days 1 and 8 of each cycle, and a
new cycle began on day 22. Patients who developed phlebitis were allowed
to receive the drugs every two weeks. Patients with bulky mediastinal
disease received involved field radiation therapy after chemotherapy.
Fifty-one patients were treated. Complete remission was achieved in 40
patients (78%). Actuarial failure-free survival in 55 months was 59%,
and overall survival was 81%. The overall survival for the 32 patients
treated with the intensified regimen was higher than that for those who
switched to the bi-weekly schedule (89% vs. 68%, p=0.03). ABVP appears
to be equivalent to ABVD. The higher overall survival rate in patients
treated every 21 days suggests that this intensified schedule might be
more effective. The placement of a Port catheter is recommended, due to
the high incidence of phlebitis.
16
UI - 11991586
AU - Yencha MW
TI -
Primary parotid gland Hodgkin's lymphoma.
SO - Ann Otol Rhinol Laryngol 2002 Apr;111(4):338-42
AD - Department of Otolaryngology-Head and Neck Surgery, Naval Hospital,
Pensacola, Florida, USA.
Hodgkin's lymphoma with its primary manifestation in the parotid gland
is an exceedingly rare entity and is not usually suspected in the
initial evaluation of a parotid mass. Because it is not suspected, the
results of fine-needle aspiration cytology are often misleading, and
parotidectomy is needed for a definitive diagnosis. The most common
subtype encountered is lymphocyte-predominant. The prognosis is
favorable; the 5-year survival rate exceeds 90%. Treatment consists of
chemotherapy, radiotherapy, or both. A case of primary parotid gland
Hodgkin's lymphoma is presented along with a review of the literature
and a discussion of the evaluation and management of this rare entity.
17
UI - 11869963
AU - Vassallo J; Metze K; Traina F; de Souza CA; Lorand-Metze I
TI -
Further remarks on the expression of CD20 in classical Hodgkin's
lymphomas.
SO - Haematologica 2002 Mar;87(3):ELT17
18
UI - 11892016
AU - Iyengar KR; Mutha S
TI -
Discrete epithelioid cells: useful clue to Hodgkin's disease
cytodiagnosis.
SO - Diagn Cytopathol 2002 Mar;26(3):142-4
AD - Department of Pathology, Jawaharlal Institute of Postgraduate Medical
Education and Research, Pondicherry 605006, India.
Diagnosis of Hodgkin's disease is made with more confidence than
diagnosis of non-Hodgkin's lymphoma on cytology. This study was
undertaken to describe the presence of granulomas and a new cytologic
feature, discrete epithelioid cells (DECs), in smears from Hodgkin's
disease. Fine-needle aspiration smears from 39 cases of biopsy-proven
Hodgkin's disease, collected over a period of 43 months, were reviewed.
Epithelioid granulomas were seen in 38.5% of the smears. DECs, which
were noted in 70% of the cases, may be useful in raising the suspicion
of Hodgkin's disease when other features are not evident; their presence
should encourage the cytopathologist to obtain aspirations from other
lymph nodes. Copyright 2002 Wiley-Liss, Inc.
19
UI - 11953894
AU - Re D; Wickenhauser C; Ahmadi T; Buchdunger E; Kochanek M; Diehl V; Wolf
TI -
J
Preclinical evaluation of the antiproliferative potential of STI571 in
Hodgkin's disease.
SO - Br J Cancer 2002 Apr 22;86(8):1333-5
AD - Department of Internal Medicine I, University of Cologne,
Joseph-Stelzmann-Strasse 9, 50931 Cologne, Germany.
STI571 is a selective tyrosine kinase inhibitor with proven therapeutic
potential in malignancies expressing c-kit. A strong c-kit and stem cell
factor expression was detected in the Hodgkin and Reed Sternberg cell
line L1236, but not in 20 primary cases of classical Hodgkin's disease.
Proliferation of L1236 cells was neither affected by addition of stem
cell factor nor by neutralising anti-stem cell factor antibodies or
STI571. Results suggest that patients with Hodgkin's disease may not
benefit from therapy with STI571. Copyright 2002 Cancer Research UK
20
UI - 12002116
AU - Kotila TR; Aken'ova YA; Shokunbi WA; Akingbola TS; Fasola FA
TI -
Hodgkin's disease after treatment for Burkitt's lymphoma: case report.
SO - East Afr Med J 2001 Jun;78(6):334-6
AD - Department of Haematology, College of Medicine, University of Ibadan,
Nigeria.
Hodgkin's disease and non-Hodgkin's lymphomas are interrelated disorders
which have been reported to occur either simultaneously or sequentially
in the same patient. We report here the development of nodular
sclerosing type Hodgkin's disease in a patient two decades after
successful treatment for Burkitt's lymphoma with cyclophosphomide and
abdominal resection (AR). While the onset of symptoms after treatment
for Burkitt's lymphoma was seven years definitive diagnosis of Hodgkin's
disease was only made 22 years after the initial diagnosis of Burkitt's
lymphoma. The recurrent and solitary nature ofthe lymphadenopathy and
the fact that it was initially reported as reactive hyperplasia is
typical of nodular lymphocyte predominant Hodgkin's disease. We believe
that there was a transitory period of the malignancy as nodular
lymphocyte predominant Hodgkin's disease.
21
UI - 11816548
AU - Di Fiore F; Savoye-Collet C; Savoye G; Foresier F; Koning FE; Scotte M;
TI -
Seng SH; Lerebours E
Magnetic resonance cholangiographic assessment of a delayed
radiation-induced bile duct stricture.
SO - Dig Liver Dis 2001 Oct;33(7):584-6
AD - Digestive Disease Tract Research Group, Rouen University Hospital
Charles Nicolle, France.
Radiation-induced bile duct strictures are rare since bile ducts are
considered to be resistant in radiation injury. We report a case of bile
duct stenosis where evidence is presented that bile duct stricture was
the result of radiation injury and which illustrates the major
contribution of magnetic res-onance cholangiography in biliary tract
disease evaluation.
22
UI - 11839668
AU - Rassidakis GZ; Medeiros LJ; McDonnell TJ; Viviani S; Bonfante V; Nadali
TI -
G; Vassilakopoulos TP; Giardini R; Chilosi M; Kittas C; Gianni AM;
Bonadonna G; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease:
correlation with clinical outcome.
SO - Clin Cancer Res 2002 Feb;8(2):488-93
AD - Department of Lymphoma-Myeloma, University of Texas M. D. Anderson
Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
gzrassidakis@mail.mdanderson.org
PURPOSE: BAX, a proapoptotic member of the BCL-2 family of proteins, has
been detected in Hodgkin and Reed-Sternberg (HRS) cells of Hodgkin's
disease (HD), but its clinical significance is unknown. Therefore, we
correlated BAX expression with presenting features and clinical outcome
in untreated patients with HD. DESIGN: Patients with biopsy-proven HD
were eligible if they were untreated previously and if pretreatment
paraffin-embedded tumor tissue was available. BAX was detected by
immunohistochemistry without knowledge of clinical features or outcome.
A tumor was considered as positive if any number of HRS cells expressed
BAX, but other cutoffs of BAX expression were examined for analysis of
clinical outcome. RESULTS: We identified 260 patients with HD. The
median age was 31 years, and 55% were male. HRS cells expressed BAX in
181 of 195 (93%) nodular sclerosis, 47 of 48 (98%) mixed cellularity, 1
case of lymphocyte depletion, all 6 unclassified classical HD, and all
10 lymphocyte predominance tumors. Using a cutoff of 50% positive HRS
cells for BAX expression, the 5-year failure-free survival (FFS) for
patients with high versus low BAX expression was 83 versus 93%,
respectively (P = 0.19 by Log-rank) for 116 patients treated with
doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent
regimens; it was 78 versus 79%, respectively, for 79 patients treated
with mitoxantrone, vincristine, vinblastine, and prednisone and
radiotherapy (P = 0.45 by Log-rank); it was 71 versus 81%, respectively,
for 26 patients treated with nitrogen mustard, vincristine, prednisone,
and procarbazine (P = 0.6 by Log-rank); and it was 72 versus 82% for 29
patients treated only with radiotherapy (P = 0.57 by Log-rank). The
5-year FFS was not statistically different when we used cutoffs of 20,
30, and 75% for BAX expression. CONCLUSION: BAX is often expressed by
HRS cells in HD and does not correlate with FFS.
23
UI - 11980993
AU - Prosnitz LR
TI -
Reducing treatment-related morbidity and mortality in early-stage
Hodgkin's disease and why the recent Southwest Oncology Group Trial is
not the way to go.
SO - J Clin Oncol 2002 May 1;20(9):2225-8
24
UI - 11412652
AU - Navarro B; Yebra M; Romero J; Suarez-Massa D
TI -
[Hodgkin lymphoma associated with primary Sjogren's syndrome]
SO - Med Clin (Barc) 2001 May 5;116(16):636
25
UI - 11872338
AU - Thomson AB; Wallace WH
TI -
Treatment of paediatric Hodgkin's disease. a balance of risks.
SO - Eur J Cancer 2002 Mar;38(4):468-77
AD - Department of Haematology/Oncology, Royal Hospital for Sick Children, 17
Millerfield Place, EH9 1LW, Edinburgh, UK.
Hodgkin's disease is one of the commoner malignancies presenting in
adolescence and young adulthood and is curable in the majority of cases.
A number of therapeutic regimens have been used successfully, often at
the expense of the development of side-effects in later life, including
second malignancies, infertility and cardiac disease. We discuss the
challenge faced by paediatric oncologists today in finding the balance
between maximising cure and minimising the late effects.
26
UI - 11905746
AU - Stephenson J
TI -
Immunotherapy shows promise in Hodgkin's disease.
SO - Lancet Oncol 2001 Jun;2(6):329
27
UI - 11958663
AU - Bairey O; Pazgal I; Okon E; Shaklai M; Morgenshtern S
TI -
Lack of HER-2/neu expression in Hodgkin and non-Hodgkin lymphoma.
SO - Arch Pathol Lab Med 2002 May;126(5):574-6
AD - Institutes of Hematology, Rabin Medical Center, Beilinson Campus, Petah
Tiqva, Israel. obairey@post.tau.ac.il
OBJECTIVE: Overexpression of HER-2/neu oncoprotein, a tyrosine kinase
receptor, occurs in a variety of human cancers and has been shown to
play a critical role in their development. This overexpression is
usually associated with poor clinical outcome. The significance of
HER-2/neu in lymphomas is unknown. The aim of this study was to evaluate
the expression of HER-2/neu in the malignant lymphomas: non-Hodgkin and
Hodgkin lymphomas. METHODS: We studied formalin-fixed, paraffin-embedded
tissue from 50 patients with lymphoma. Forty-two specimens were from
patients with various types of non-Hodgkin lymphoma, and 8 were from
patients with Hodgkin lymphoma. HER-2/neu expression was examined by an
immunohistochemical technique using the HercepTest. RESULTS: None of the
specimens demonstrated overexpression or even any expression of
HER-2/neu. Reactive plasma cells showed cytoplasmic staining, which was
not found in malignant plasma cells from patients with multiple myeloma.
CONCLUSIONS: Non-Hodgkin and Hodgkin lymphomas do not express the
HER-2/neu oncoprotein. This finding suggests that HER-2/neu does not
play a role in these diseases.
28
UI - 12007954
AU - McAfee SL; Powell SN; Colby C; Spitzer TR
TI -
Dose-escalated total body irradiation and autologous stem cell
transplantation for refractory hematologic malignancy.
SO - Int J Radiat Oncol Biol Phys 2002 May 1;53(1):151-6
AD - Department of Medicine, Bone Marrow Transplantation Program,
Massachusetts General Hospital and Harvard Medical School, 55 Fruit
Street, Boston, MA 02114, USA.
PURPOSE: To evaluate the feasibility of dose escalation of total body
irradiation (TBI) above the previously reported maximally tolerated
dose, we have undertaken a Phase I-II trial of dose-escalated TBI with
autologous peripheral blood stem cell transplantation (PBSCT) for
chemotherapy-refractory lymphoma. METHODS AND MATERIALS: Nine lymphoma
patients with primary refractory disease (PRD) or in resistant relapse
(RR) received dose-escalated TBI and PBSCT. The three dose levels of
fractionated TBI (200 cGy twice daily) were 1,600 cGy, 1,800 cGy, and
2,000 cGy. Lung blocks were used to reduce the TBI transmission dose by
50%, and the chest wall dose was supplemented to the prescribed dose
using electrons. Shielding of the kidneys was performed to keep the
maximal renal dose at 1,600 cGy. Three patients, two with non-Hodgkin's
lymphoma (NHL) in RR and one with PRD Hodgkin's disease, received 1,600
cGy + PBSCT, three patients (two NHL in RR, one PRD) received 1,800 cGy
+ PBSCT, and three patients with NHL (two in RR, one PRD) received 2,000
cGy + PBSCT. RESULTS: Toxicities associated with this high-dose TBI
regimen included reversible hepatic veno-occlusive disease in 1 patient,
Grade 2 mucositis requiring narcotic analgesics in 8 patients, and
neurologic toxicities consisting of a symmetrical sensory neuropathy (n
= 4) and Lhermitte's syndrome (n = 1). Interstitial pneumonitis
developed in 1 patient who received 1,800 cGy after receiving
recombinant alpha-interferon (with exacerbation after rechallenge with
interferon). Six (66%) patients achieved a response. Four (44%) patients
achieved complete responses, three of which were of a duration greater
than 1 year, and 2 (22%) patients achieved a partial response. One
patient remains disease-free more than 5 years posttransplant.
Corticosteroid-induced gastritis and postoperative infection resulted in
the death of 1 patient in complete response, 429 days posttransplant.
CONCLUSION: TBI in a dose range 1,600-2,000 cGy as preparative therapy
for autologous PBSCT is feasible and has substantial activity in
chemorefractory non-Hodgkin's and Hodgkin's lymphoma.
29
UI - 11920819
AU - Kim I; Park ER; Park SH; Lin Z; Kim YS
TI -
Characteristics of Epstein-Barr virus isolated from the malignant
lymphomas in Korea.
SO - J Med Virol 2002 May;67(1):59-66
AD - Department of Pathology, Korea University Medical College, Seoul, Korea.
iskim@korea.ac.kr
Epstein-Barr virus (EBV) is a common herpes virus linked to a variety of
human neoplasms. In this study, the EBV detection was identified with
the paraffin-embedded tissues from 62 non-Hodgkin's lymphomas, 20
Hodgkin's lymphomas, and 48 non-neoplastic tonsils, using PCR for EBNA-1
and EBER-1 mRNA in situ hybridization for EBER-1 mRNA. The isolates were
analyzed for type 1/2, variants C/D and F/f, and LMP-1 30 bp deletion.
EBV was isolated in 31 of 48 (66%) non-neoplastic tonsils, 24 of 42
(57%) B cell lymphomas, in 15 of 20 (75%) T cell lymphomas, and 17 of 20
(85%) Hodgkin's lymphomas. These viruses were classified as type 1 for
81% of non-neoplastic tonsils, 95% of B cell lymphomas, 93% of T cell
lymphomas, and 73% of Hodgkin's diseases. Both type 1 and 2 viruses were
isolated in one non-neoplastic tonsil and 3 Hodgkin's diseases. Type C
virus was predominant in non-neoplastic tonsils (77%) and B cell
lymphomas (75%), while type D virus was common in T cell lymphomas (71%)
and Hodgkin's diseases (73%) (P < 0.05). Majority of the viruses
detected in non-neoplastic tonsils (93%) and malignant lymphomas (91%)
were "F" prototype. LMP-1 30 bp deletion was found in high frequency in
both non-neoplastic tonsils (92%) and malignant lymphomas (86%). In
conclusion, most of EBV found in Korea was type 1, and "DF" genotype was
more frequent in T cell lymphomas and Hodgkin's diseases than in
non-neoplastic tonsils and B cell lymphomas. LMP-1 30 bp deletion did
not seem to be associated with malignant lymphomas. Copyright 2002
Wiley-Liss, Inc.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
